Myriad Genetics
在场
是其中之一......
Myriad Genetics 是一家在股票代码 MYGN (US) 下上市的公司。
Myriad Genetics 在 2 个国家有直接业务。Myriad Genetics 拥有 4家子公司，其中包括 GeneSight、Myriad Genetics Europe 和 Myriad RBM。
他们在：
高管
查看带有其 43 名主要高管的组织结构图
Myriad Genetics 搜索最多的简介
- Paul Diaz, Director, President and Chief Executive Officer
- Heiner Dreismann, Director
- Lee Newcomer, Director
高管在Myriad Genetics变化
- Jennifer Fox已作为Chief Legal Officer加入公司 (新闻发布的2024八月1号).
创建提醒
跟踪 Myriad Genetics 的高管变动
药店
Myriad Genetics 拥有 1,837 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Myriad Genetics 的最新新闻稿
- Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- News Release Detail | Myriad GeneticsClose this dialogClose Cookie Preferences
- Myriad Genetics to Host Investor Event on October 9, 2024
- Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
- Myriad Genetics Earns 2024 Great Place To Work® Certification™
- Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
- View more press releases Close
通过电子邮件
